Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia

This study has been completed.
Sponsor:
Collaborator:
Hammersmith Hospitals NHS Trust
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00230659
First received: September 29, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted

September 29, 2005
September 29, 2005
August 2004
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia
Investigation of Coagulation Parameters in Hereditary Haemorrhagic

The inherited disease hereditary haemorrhagic telangiectasia (HHT) causes bleeding from dilated fragile vessels, particularly in the nose and gut. However, many HHT patients develop deep venous thromboses and/or pulmonary embolism, necessitating treatments with anticoagulants that further impair control of their haemorrhagic state. Our initial observations using general coagulation tests suggest that the blood of HHT patients is intrinsically hypercoagulable.

We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of one or several of the proteins which affect blood clotting leading to a hypercoagulable state.

We propose to study levels and activity of blood coagulation factors in people with hereditary haemorrhagic telangiectasia and in normal volunteers. This should define the significance and basis for our initial observations, and will have significant implications for the clinical management of HHT patients.

Not Provided
Observational
Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Telangiectasia, Hereditary Hemorrhagic
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
Not Provided
Not Provided

Inclusion Criteria:

  • Patients with HHT and normal controls

Exclusion Criteria:

  • Previous thrombosis, recent ill health
Both
Not Provided
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00230659
IC/CLS6
Not Provided
Not Provided
Imperial College London
Hammersmith Hospitals NHS Trust
Principal Investigator: Claire Shovlin Imperial College London
Imperial College London
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP